DOCSLIB.ORG

CD Antigens 1993: an Updated Nomenclature for Clusters of Differentiation on Human Cells* IUIS/WHO Subcommittee on CD Nomenclature'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CD Antigens 1993: an Updated Nomenclature for Clusters of Differentiation on Human Cells* IUIS/WHO Subcommittee on CD Nomenclature' CD antigens 1993: an updated nomenclature for clusters of differentiation on human cells* IUIS/WHO Subcommittee on CD Nomenclature' The 5th International Workshop on Human Leukocyte Differentiation Antigens (Boston, USA, 3-7 November 1993) recommended the adoption of 48 new CD clusters and subclusters and the redefinition of 14 previously established clusters. The additions and changes made to the existing CD nomenclature are summarized in a Table. Introduction in the latter instance, the letter R is followed by a let- ter corresponding to relevant exons. The nomenclature for clusters of differentiation (CD), which is dedicated to the designation of cell surface structures of human cells, was established by Results the International Workshop on Human Leukocyte Differentiation Antigens and continues to be updated The results of the 5th Intemational Workshop on by these Workshops. The CD nomenclature was ini- Human Leukocyte Differentiation Antigens were tially proposed to cluster monoclonal antibodies presented on 3-7 November 1993 at a meeting in (mAbs) of different sources that recognize the same Boston, MA, USA. The participants represented the human leukocyte differentiation antigen. The nomen- efforts of more than 500 laboratories worldwide, clature is based on analysis of the results of blinded which joined together over a two-year period to ana- studies of the molecular mass of antigens recognized lyse 1450 antibodies and characterize over 150 mole- by mAbs submitted for evaluation to the Workshop cules. Blind panels for all monoclonal antibodies and of the reactivity of the mAbs with target cells. (mAbs), every CD antigen, every known candidate The nomenclature was aimed to be simple, unambi- for CD status, and all mAbs of undefined specificity guous and adaptable. were analysed by flow cytometry. Other dedicated The CD nomenclature is now widely used to laboratories undertook serological, molecular, bio- designate the molecular species recognized by a chemical and histochemical characterization of the mAb. New mAbs are characterized and therefore mAbs and the structures they defined. The results new CD antigens are defined after each International obtained by all groups showed almost perfect Workshop. In addition, the CDw ("Workshop") des- concordance. ignation is attributed to either (1) a single mAb rec- Detailed results of these studies will be pub- ognizing the cell surface product of a transfected lished separately.a In addition, a Leukocyte Differen- gene, or (2) a new molecule identified by one or two tiation Antigen Database (LDAD) has been devel- mAbs generated in the same laboratory. The CD # R oped to (1) provide identifying information on all symbols are given to indicate that the tissue distribu- molecules and mAbs studied in the Workshop, and tion of CD # may be restricted. In some cases the (2) display/analyse the quantitative expression of restriction has been attributed to alternative splicing; each molecule on more than 80 cell types.b Based on these findings, the Workshop recommends the adop- tion of 48 new CD clusters and subclusters and the redefinition of 14 previously established clusters. * This report has been approved by the IUIS/WHO Nomencla- The additions and changes made to the existing CD ture Committee. A resume in French appears on page 808. nomenclature are summarized in Table 1. Requests for reprints should be addressed to the Chairman of the IUIS Nomenclature Committee, Professor Michel Kazatchki- ne, Unite d'Immunologie, H6pital Broussais, 96 rue Didot, 75014 Paris, France. a 1 Schlossmann SF et al., eds. White cell differentiation anti- The Subcommittee's members are S.F. Schlossmann (Chair- gens. Oxford, Oxford University Press, 1994 (in press). man), L. Boumsell, W. Gilks, J.M. Harlan, T. Kishimoto, C. Mori- b moto, J. Ritz, S. Shaw, R.L. Silverstein, T.A. Springer, T.F. Ted- The LDAD program runs on IBM PCs and via emulation on der and R.F. Todd. Macintosh. It may be downloaded freely via anonymous ftp from balrog.nci.nih.gov (156.40.182.2) or purchased on disk (inquiries Reprint No. 5532 by fax 301-480-2052). Bulletin of the World Health Organization, 1994, 72 (5): 807-808 807 IUIS/WHO Subcommittee on CD Nomenclature Table 1: CD antigens 1993 Table 1: continued CD Desig- Common Workshop Mol. mass CD99 E2, MIC2 T Cell 32 nation name section reduced CD99R CD99 mAb restricted T Cell 32 CD100 BB18, A8 T Cell 150 CD1 5s sLex, Sialyl Lewis x Adhesion CDw1O1 BB27, BA27 T Cell 140 CD16 FcR IIIA/FcR IIIB Myeloid 50-65 CD102 ICAM-2 Adhesion 60 CD1 6b FcR IIIB Myeloid 48 CD1 03 HML-1 Adhesion 150,25 CD32 Previously CDw32, FcRII Myeloid 40 CD104 f4 integrin chain Adhesion 220 CD42a GPIX Platelets 23 CD42b GPIB, a Platelets 135,23 CD105 Endoglin Endothelial 95 CD42c GP1 B-I Platelets 22 CD106 VCAM-1, INCAM-110 Endothelial 100,110 CD42d GPV Platelets 85 CD107a LAMP-1 Platelet 110 CD44 Pgp-1 Adhesion 80-90 CD107b LAMP-2 Platelet 120 CD44R Restricted epitope on CD44 Adhesion CDw1 08 Adhesion 80 CD49a VLA-1, al integrin chain Adhesion 210 CDw1 09 8A3, 7D1 Endothelial 170,150 CD49b VLA-2, a2 integrin chain Adhesion 160 CD1 15 CSF-1R; M-CSFR Myeloid 150 CD49c VLA-3, a3 integrin chain Adhesion 125 CDwl 16 HGM-CSFR, GM-CSFR Cytokine 75-85 CD49d VLA-4, a4 integrin chain Adhesion 150,80,70 CD1 17 SCFR, cKIT Cytokine 145 CD49e VLA-5, a5 integrin chain Adhesion 135,25 CDwl 19 IFNyR Cytokine 90 CD49f VLA-6, a6 integrin chain Adhesion 120,25 CD120a TNFR;55kD Cytokine 55 CD50 ICAM-3 Adhesion 124 CD120b TNFR;75kD Cytokine 75 CD51/ Complex dependent epitope Adhesion CDwl 21 a IL-1 R;Typel Cytokine 80 CD61 CDwl21b IL-1 R;Type2 Cytokine 68 CD52 Campath-1 Blind 21-28 CD122 IL-2R;75kD, IL-2RP Cytokine 75 CDw1 24 IL-4R Cytokine 140 CD62E ELAM-1 Adhesion 115 E-selectin, CD126 IL-6R Cytokine 80 CD62L L-selectin, LAM-1, TQ-1 Adhesion 75-80 CDw1 27 IL-7R Cytokine 75 CD62P P-selectin, GMP-140, Adhesion 150 CDw1 28 IL-8R Cytokine 57-67 PADGEM CDw1 30 IL-6R-GP130SIG Cytokine 130 CD66a BGP Myeloid 180-200 CD66b CD67, p100, CGM6 Myeloid 95-100 CD66c NCA Myeloid 90-95 CD66d CGM1 Myeloid 30 CD66e CEA, carcinoembryonic Myeloid 180-200 Resume antigen Les CD en 1993: nomenclature r6visee CD67 Now CD66b CD70 CD27-ligand Activation 55,75,95, des antigenes de classe de diff6renciation 110,170 pr6sents sur les cellules humaines CDw76 Previously CD76 B Cell NA La nomenclature applicable aux antigenes des CD79a mb-1, Iga B Cell 33,40 CD79b B29, lgt B Cell 33,40 classes de diff6renciation (CD), qui consiste a CD80 B7, BB1 B Cell 60 d6signer les structures presentes a la surface des CD81 TAPA-1 B Cell 22 cellules humaines, a 6t6 6tablie et est r6guliere- CD82 R2, IA4, 4F9 B Cell 50-53 ment mise a jour a l'occasion d'ateliers internatio- CD83 HB15 B Cell 43 naux sur les antigenes de differenciation des leu- CDw84 B Cell 73 cocytes humains. La nomenclature repose sur CD85 VMP-55, GH11/75 B Cell 120,83 deux 6l6ments: les r6sultats d'6tudes men6es en CD86 FUN-1, BU63 B Cell 80 aveugle sur la masse mol6culaire d'antigenes CD87 UPA-R Myeloid 50-65 reconnus par des anticorps monoclonaux (ACM) CD88 C5aR Myeloid 42 soumis pour 6valuation a l'atelier, et la reactivite CD89 FcaR Myeloid 55-75 des ACM avec leurs cellules cibles. CDw9O Thy-1 Myeloid 25-35 Le 5e atelier international sur les antigenes CD91 a2M-R Myeloid 600 de diff6renciation des leucocytes humains (3-7 CDw92 Myeloid 70 novembre 1993, Boston, Etats-Unis d'Am6rique) a CD93 Myeloid 120 recommand6 I'adoption de 48 classes et sous- CD94 KP43 NK Cell 43 classes nouvelles de differenciation ainsi que la CD95 APO-1, FAS Activation 42 redefinition de 14 classes pr6cedemment 6tablies. CD96 TACTILE Activation 160 Les adjonctions et les modifications apport6es a CD97 Activation 74,80,89 la nomenclature existante des CD sont r6sum6es CD98 4F2, 2F3 T Cell 80,40 dans un tableau. 808 WHO Bulletin OMS. Vol 72 1994.
Load more

Recommended publications
  • Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
    International Journal of Molecular Sciences Review Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy Jianguang Zhang, Huifang Zheng and Yong Diao * School of Medicine, Huaqiao University, Quanzhou 362021, Fujian, China; [email protected] (J.Z.); [email protected] (H.Z.) * Correspondence: [email protected]; Tel.: +86-595-2269-2516 Received: 15 November 2018; Accepted: 11 January 2019; Published: 14 January 2019 Abstract: Natural killer (NK) cells are innate immune cells that can be activated rapidly to target abnormal and virus-infected cells without prior sensitization. With significant advancements in cell biology technologies, many NK cell lines have been established. Among these cell lines, NK-92 cells are not only the most widely used but have also been approved for clinical applications. Additionally, chimeric antigen receptor-modified NK-92 cells (CAR-NK-92 cells) have shown strong antitumor effects. In this review, we summarize established human NK cell lines and their biological characteristics, and highlight the applications of NK-92 cells and CAR-NK-92 cells in tumor immunotherapy. Keywords: natural killer cell line; NK-92; chimeric antigen receptor; immunotherapy; tumor 1. Introduction Natural killer (NK) cells are innate immune cells that were first discovered in mice in 1975 [1]. NK cells account for approximately 10% of lymphocytes in human peripheral blood (PB). Owing to the distinct chemokine receptors expressed in NK cells, the distributions of NK cells differ among healthy tissues. Most NK cells are found in the PB, liver, spleen, and bone marrow, and a small portion are also present in the lymph nodes [2–5].
    [Show full text]
  • Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species
    International Journal of Molecular Sciences Review Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species Mohammed Yusuf Zanna 1 , Abd Rahaman Yasmin 1,2,* , Abdul Rahman Omar 2,3 , Siti Suri Arshad 3, Abdul Razak Mariatulqabtiah 2,4 , Saulol Hamid Nur-Fazila 3 and Md Isa Nur Mahiza 3 1 Department of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] 2 Laboratory of Vaccines and Biomolecules, Institute of Bioscience, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] (A.R.O.); [email protected] (A.R.M.) 3 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] (S.S.A.); [email protected] (S.H.N.-F.); [email protected] (M.I.N.M.) 4 Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia * Correspondence: [email protected]; Tel.: +603-8609-3473 or +601-7353-7341 Abstract: Dendritic cells (DCs) are cells derived from the hematopoietic stem cells (HSCs) of the bone marrow and form a widely distributed cellular system throughout the body. They are the most effi- cient, potent, and professional antigen-presenting cells (APCs) of the immune system, inducing and dispersing a primary immune response by the activation of naïve T-cells, and playing an important role in the induction and maintenance of immune tolerance under homeostatic conditions. Thus, this Citation: Zanna, M.Y.; Yasmin, A.R.; review has elucidated the general aspects of DCs as well as the current dynamic perspectives and Omar, A.R.; Arshad, S.S.; distribution of DCs in humans and in various species of animals that includes mouse, rat, birds, dog, Mariatulqabtiah, A.R.; Nur-Fazila, cat, horse, cattle, sheep, pig, and non-human primates.
    [Show full text]
  • CD2 Molecules Redistribute to the Uropod During T Cell Scanning: Implications for Cellular Activation and Immune Surveillance
    CD2 molecules redistribute to the uropod during T cell scanning: Implications for cellular activation and immune surveillance Elena V. Tibaldi*†, Ravi Salgia†‡, and Ellis L. Reinherz*†§ *Laboratory of Immunobiology and ‡Division of Adult Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, and †Department of Medicine, Harvard Medical School, Boston, MA 02115 Communicated by Stuart F. Schlossman, Dana-Farber Cancer Institute, Boston, MA, April 9, 2002 (received for review February 14, 2002) Dynamic binding between CD2 and CD58 counter-receptors on op- cells, whereas its counter-receptor CD58 is expressed on a posing cells optimizes immune recognition through stabilization of diverse array of nucleated and non-nucleated cells including cell–cell contact and juxtaposition of surface membranes at a distance APCs and stromal cells (reviewed in refs. 11 and 12). CD2 suitable for T cell receptor–ligand interaction. Digitized time-lapse functions in both T cell adhesion and activation processes (13). Ϸ differential interference contrast and immunofluorescence micros- Of note, the weak affinity of the CD2-CD58 interaction (Kd copy on living cells now show that this binding also induces T cell 1 ␮M) is associated with remarkably fast on and off rates that polarization. Moreover, CD2 can facilitate motility of T cells along foster rapid and extensive exchange between CD2 and CD58 antigen-presenting cells via a movement referred to as scanning. Both partners on opposing cell surfaces (14–16). These biophysical activated CD4 and CD8 T cells are able to scan antigen-presenting cells characteristics are reminiscent of the selectin–ligand interactions surfaces in the absence of cognate antigen.
    [Show full text]
  • Human Fcgr2a / Cd32a (H131) Protein Catalog # AMS.CD1-H5223-100UG for Research Use Only
    Human FcGR2A / CD32a (H131) Protein Catalog # AMS.CD1-H5223-100UG For Research Use Only Description Source Human FcGR2A / CD32a (H131) Protein,also called Human FcGR2A / CD32a Protein (167 His), Ala 36 - Ile 218 (Accession # P12318-1), was produced in human 293 cells (HEK293) Predicted N-terminus Ala 36 Protein Structure Molecular Human FcGR2A / CD32a (H131), His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 21.1 Characterization kDa. The predicted N-terminus is Ala 36. The reducing (R) protein migrates as 29-32 kDa in SDS-PAGE due to glycosylation. Endotoxin Less than 1.0 EU per μg by the LAL method. >95% as determined by SDS-PAGE. Purity Bioactivity The bioactivity is measured by its binding ability to Ipilimumab in a SPR assay. Immobilized Human FcGR2A / CD32a (H131), His Tag (Cat# AMS.CD1-H5223-100UG) can bind Ipilimumab with affinity constant of around 2.7 uM. Measured by its binding ability in a functional ELISA. Immobilized human IgG4 at 10μg/mL (100 µl/well),can bind Human FcGR2A / CD32a (H131), His Tag (Cat# AMS.CD1-H5223-100UG) with a linear of 0.1-2 μg/mL. Formulation and Storage Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation. Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the Reconstitution reconstitution protocol provided in the COA. Storage For long term storage, the product should be stored at lyophilized state at -20°C or lower.
    [Show full text]
  • REVIEW Dendritic Cell-Based Vaccine
    Leukemia (1999) 13, 653–663 1999 Stockton Press All rights reserved 0887-6924/99 $12.00 http://www.stockton-press.co.uk/leu REVIEW Dendritic cell-based vaccine: a promising approach for cancer immunotherapy K Tarte1 and B Klein1,2 1INSERM U 475, Montpellier; and 2Unit For Cellular Therapy, CHU Saint Eloi, Montpellier, France The unique ability of dendritic cells to pick up antigens and to + + and interstitial DC pick up antigens (Ag) in peripheral tissues activate naive and memory CD4 and CD8 T cells raised the and migrate to lymphoid organs through lymphatic vessels in possibility of using them to trigger a specific anti-tumor 8 immunity. If numerous studies have shown a major interest in response to inflammatory stimuli. Activated mature DC, dendritic cell-based vaccines for cancer immunotherapy in ani- which express CD1a and CD83 antigens, represent the latter mal models, only a few have been carried out in human can- stage of LC and interstitial DC maturation. According to their cers. In this review, we describe recent findings in the biology high expression of MHC class I, MHC class II and costimu- of dendritic cells that are important to generate anti-tumor cyto- latory molecules, they present, efficiently, Ag-derived peptides toxic T cells in vitro and we also detail clinical studies reporting to CD4+ and CD8+ T lymphocytes in lymph node T cell areas the obtention of specific immunity to human cancers in vivo using reinfusion of dendritic cells pulsed with tumor antigens. (Figure 1). Recently, another subset of DC was identified on Keywords: dendritic cells; cancer; immunotherapy the basis of their high expression of the interleukin-3 receptor alpha chain (IL-3R␣hi).
    [Show full text]
  • Mechanisms and Consequences of Antigen Presentation By
    Series: The Biology of Antigen Presentation Feature Review Mechanisms and Consequences of Antigen Presentation by CD1 1, 1 1,2 Luc Van Kaer, * Lan Wu, and Sebastian Joyce The CD1 proteins are a family of non-polymorphic and MHC class I-related Trends molecules that present lipid antigens to subsets of T lymphocytes with innate- or The CD1–lipid presentation system adaptive-like immune functions. Recent studies have provided new insight into allows the immune system to sense alterations in lipid homeostasis, and the identity of immunogenic CD1 antigens and the mechanisms that control the complements the classical MHC–pep- generation and loading of these antigens onto CD1 molecules. Furthermore, tide presentation system. There are substantial progress has been made in identifying CD1-restricted T cells and remarkable similarities and surprising differences in the way that TCRs decoding the diverse immunological functions of distinct CD1-restricted T cell engage CD1–lipid versus MHC–pep- subsets. These findings shed new light on the contributions of the CD1 antigen- tide complexes. presentation pathway to normal health and to a diverse array of pathologies, and Group 1 CD1 proteins (CD1a–c) pre- provide a new impetus for exploiting this fascinating recognition system for the sent a variety of endogenous, myco- development of vaccines and immunotherapies. bacterial, and potentially other bacterial lipids to T cells. CD1b-restricted T cells include subsets expressing germline- Antigen-Presentation Systems encoded TCRs. Products encoded by the major histocompatibility complex (MHC) region of the vertebrate Group 2 CD1 proteins (CD1d) present genome bind peptide fragments from pathogens and display them at the surface of antigen- diverse endogenous and exogenous presenting cells (APCs) for appraisal by T lymphocytes [1].
    [Show full text]
  • Cells and Marginal Zone B Cells CD1.1 Expression by Mouse Antigen-Presenting
    CD1.1 Expression by Mouse Antigen-Presenting Cells and Marginal Zone B Cells Jessica H. Roark, Se-Ho Park, Jayanthi Jayawardena, Uma Kavita, Michele Shannon and Albert Bendelac This information is current as of September 29, 2021. J Immunol 1998; 160:3121-3127; ; http://www.jimmunol.org/content/160/7/3121 References This article cites 48 articles, 26 of which you can access for free at: Downloaded from http://www.jimmunol.org/content/160/7/3121.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on September 29, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1998 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. CD1.1 Expression by Mouse Antigen-Presenting Cells and Marginal Zone B Cells1 Jessica H. Roark, Se-Ho Park, Jayanthi Jayawardena, Uma Kavita, Michele Shannon, and Albert Bendelac2 Mouse CD1.1 is an MHC class I-like, non-MHC-encoded, surface glycoprotein that can be recognized by T cells, in particular NK1.11 T cells, a subset of ab T cells with semiinvariant TCRs that promptly releases potent cytokines such as IL-4 and IFN-g upon stimulation.
    [Show full text]
  • Low-Affinity B Cells Transport Viral Particles from the Lung to the Spleen to Initiate Antibody Responses
    Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses Juliana Bessaa, Franziska Zabelb, Alexander Linka, Andrea Jegerlehnera, Heather J. Hintona, Nicole Schmitza,1, Monika Bauera, Thomas M Kündigb, Philippe Saudana, and Martin F. Bachmannb,2 aResearch Department, Cytos Biotechnology, CH-8952 Zurich-Schlieren, Switzerland; and bDepartment of Dermatology, Zurich University Hospital, 8091 Zurich, Switzerland Edited* by Rafi Ahmed, Emory University, Atlanta, GA, and approved October 19, 2012 (received for review April 27, 2012) The lung is an important entry site for pathogens; its exposure to sinus macrophages within lymph nodes. Subsequently, recirculating antigens results in systemic as well as local IgA and IgG antibodies. B cells surveying the subcapsular sinus capture the trapped Ag via Here we show that intranasal administration of virus-like particles complement receptor (Cr) interactions and transport it into B-cell (VLPs) results in splenic B-cell responses with strong local germinal- FO where the Ab response is initiated (18–20). In contrast, small center formation. Surprisingly, VLPs were not transported from the Ags reach the B-cell FO either by diffusion through small gaps fl lung to the spleen in a free form but by B cells. The interaction located in the subcapsular sinus oor (16) or they are delivered to between VLPs and B cells was initiated in the lung and occurred cognate B cells and follicular dendritic cells (FDCs) by the conduit independently of complement receptor 2 and Fcγ receptors, but was system (17). Blood-derived granulocytes and DCs have also been shown to dependent upon B-cell receptors.
    [Show full text]
  • Compartments T Cell + and CD8 + Development of CD4 Comparative Contribution of CD1 On
    Comparative Contribution of CD1 on the Development of CD4 + and CD8+ T Cell Compartments This information is current as Bin Wang, Taehoon Chun and Chyung-Ru Wang of September 29, 2021. J Immunol 2000; 164:739-745; ; doi: 10.4049/jimmunol.164.2.739 http://www.jimmunol.org/content/164/2/739 Downloaded from References This article cites 57 articles, 36 of which you can access for free at: http://www.jimmunol.org/content/164/2/739.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Comparative Contribution of CD1 on the Development of CD4؉ and CD8؉ T Cell Compartments1 Bin Wang, Taehoon Chun, and Chyung-Ru Wang2 CD1 molecules are MHC class I-like glycoproteins whose expression is essential for the development of a unique subset of T cells, the NK T cells.
    [Show full text]
  • Mouse CD Marker Chart Bdbiosciences.Com/Cdmarkers
    BD Mouse CD Marker Chart bdbiosciences.com/cdmarkers 23-12400-01 CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD1d CD1.1, CD1.2, Ly-38 Lipid, Glycolipid Ag + + + + + + + + CD104 Integrin b4 Laminin, Plectin + DNAX accessory molecule 1 (DNAM-1), Platelet and T cell CD226 activation antigen 1 (PTA-1), T lineage-specific activation antigen 1 CD112, CD155, LFA-1 + + + + + – + – – CD2 LFA-2, Ly-37, Ly37 CD48, CD58, CD59, CD15 + + + + + CD105 Endoglin TGF-b + + antigen (TLiSA1) Mucin 1 (MUC1, MUC-1), DF3 antigen, H23 antigen, PUM, PEM, CD227 CD54, CD169, Selectins; Grb2, β-Catenin, GSK-3β CD3g CD3g, CD3 g chain, T3g TCR complex + CD106 VCAM-1 VLA-4 + + EMA, Tumor-associated mucin, Episialin + + + + + + Melanotransferrin (MT, MTF1), p97 Melanoma antigen CD3d CD3d, CD3 d chain, T3d TCR complex + CD107a LAMP-1 Collagen, Laminin, Fibronectin + + + CD228 Iron, Plasminogen, pro-UPA (p97, MAP97), Mfi2, gp95 + + CD3e CD3e, CD3 e chain, CD3, T3e TCR complex + + CD107b LAMP-2, LGP-96, LAMP-B + + Lymphocyte antigen 9 (Ly9),
    [Show full text]
  • CD1-Restricted T Cells During Persistent Virus Infections: “Sympathy for the Devil”
    REVIEW published: 19 March 2018 doi: 10.3389/fimmu.2018.00545 CD1-Restricted T Cells During Persistent Virus Infections: “Sympathy for the Devil” Günther Schönrich* and Martin J. Raftery Berlin Institute of Health, Institute of Virology, Charité—Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany Some of the clinically most important viruses persist in the human host after acute infection. In this situation, the host immune system and the viral pathogen attempt to establish an equilibrium. At best, overt disease is avoided. This attempt may fail, however, resulting in eventual loss of viral control or inadequate immune regulation. Consequently, direct virus-induced tissue damage or immunopathology may occur. The cluster of differentiation 1 (CD1) family of non-classical major histocompatibility complex class I molecules are known to present hydrophobic, primarily lipid antigens. There is ample evidence that both CD1-dependent and CD1-independent mechanisms activate Edited by: CD1-restricted T cells during persistent virus infections. Sophisticated viral mechanisms Luc Van Kaer, Vanderbilt University, subvert these immune responses and help the pathogens to avoid clearance from the United States host organism. CD1-restricted T cells are not only crucial for the antiviral host defense Reviewed by: but may also contribute to tissue damage. This review highlights the two edged role of Johan K. Sandberg, Karolinska Institute (KI), Sweden CD1-restricted T cells in persistent virus infections and summarizes the viral immune Randy Brutkiewicz, evasion mechanisms that target these fascinating immune cells. Indiana University Bloomington, United States Keywords: human CD1 molecules, antigen presentation, persisting viruses, viral immune evasion, NKT cells *Correspondence: Günther Schönrich INTRODUCTION [email protected] The majority of virus infections are self-limiting.
    [Show full text]
  • The A-Domain Of/32 Integrin CR3 (Cdllb/CD18) Is a Receptor for the Hookworm-Derived Neutrophil Adhesion Inhibitor
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central The A-Domain of/32 Integrin CR3 (CDllb/CD18) Is a Receptor for the Hookworm-derived Neutrophil Adhesion Inhibitor NIF Philippe Rieu, Takeo Ueda, Ikuko Haruta, Chander E Sharma, and M. Amin Arnaout Leukocyte Biology and Inflammation Program, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114 Abstract. The A-domain is a ,,o200-amino acid pep- site. The interaction of NIF with CR3 in intact cells tide present within structurally diverse proadhesive followed similar binding kinetics to those with rllbA, proteins including seven integrins. A recombinant and occurred with similar affinity in resting and acti- form of the A-domain of/32 integrins CR3 and LFA-1 vated human neutrophils, suggesting that the NIF epi- has been recently shown to bind divalent cations and tope is activation independent. Binding of NIF to CR3 to contain binding sites for protein ligands that play blocked its ability to bind to its ligands iC3b, fibrino- essential roles in leukocyte trafficking to inflammatory gen, and CD54, and inhibited the ability of human sites, phagocytosis and target cell killing. In this re- neutrophils to ingest serum opsonized particles. NIF port we demonstrate that the neutrophil adhesion in- thus represents the first example of a disintegrin that hibitor, NIF produced by the hookworm Ancylostoma targets the integrin A-domain, and is likely to be used caninum is a selective CDllb A-domain binding pro- by the hookworm to evade the host's inflammatory re- tein.
    [Show full text]